SJEPD030908_D1.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 2.57
- e1_e2
- E2
- umap1_2d
- -7.126692401
- umap2_2d
- 0.984772614
- umap1_3d
- 0.654567668
- umap2_3d
- 4.61188646
- umap3_3d
- 0.478292797
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.640
- PROTEIN_SECRETION+0.470
- BILE_ACID_METABOLISM+0.420
- ADIPOGENESIS+0.370
- ANDROGEN_RESPONSE+0.360
- HEME_METABOLISM+0.300
- FATTY_ACID_METABOLISM+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- TGF_BETA_SIGNALING+0.270
- UV_RESPONSE_DN+0.220
Top 10 suppressed
- G2M_CHECKPOINT-0.420
- E2F_TARGETS-0.400
- ANGIOGENESIS-0.390
- PANCREAS_BETA_CELLS-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- INTERFERON_ALPHA_RESPONSE-0.300
- ALLOGRAFT_REJECTION-0.280
- MYC_TARGETS_V2-0.260
- APICAL_JUNCTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_8c | EPN | Posterior Fossa EPN | 0.802 |
| 2 | s_150324_7c | EPN | Posterior Fossa EPN | 0.783 |
| 3 | MNG1214 | — | — | 0.774 |
| 4 | SRR6013501 | — | cohortA1 | 0.768 |
| 5 | s_150324_6b | EPN | Supratentorial EPN | 0.764 |
| 6 | BS_RVSEDNJ4 | Ganglioglioma | — | 0.758 |
| 7 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.754 |
| 8 | MDT-AP-0044 | Med | Medulloblastoma | 0.748 |
| 9 | SJEPD031750_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.746 |
| 10 | BS_N8J1DP02 | Posterior Fossa Ependymoma | — | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.640 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.420 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |